Kingdon Capital Management, L.L.C. Pacira Bio Sciences, Inc. Transaction History
Kingdon Capital Management, L.L.C.
- $613 Million
- Q4 2024
A detailed history of Kingdon Capital Management, L.L.C. transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Kingdon Capital Management, L.L.C. holds 195,700 shares of PCRX stock, worth $4.87 Million. This represents 0.44% of its overall portfolio holdings.
Number of Shares
195,700Holding current value
$4.87 Million% of portfolio
0.44%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding PCRX
# of Institutions
258Shares Held
49.2MCall Options Held
1.03MPut Options Held
139K-
Black Rock Inc. New York, NY8.01MShares$199 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.26MShares$131 Million0.0% of portfolio
-
Pacer Advisors, Inc. Malvern, PA3.26MShares$81.3 Million0.15% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.26MShares$56.2 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.99MShares$49.6 Million0.06% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $1.14B
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...